Andres M, De Cobelli O, Carmignani L, Musci R, Kocjancic E, Panizzutti M, Rocco F
Clinica Urologica II, Università degli Studi di Milano, Polo di Monza.
Arch Ital Urol Androl. 1995 Feb;67(1):37-9.
Benign prostatic hypertrophy provokes clinical manifestations correlated on one hand to a static obstructive component, due to the increase in glandular size, and on the other hand to a dynamic component, controlled by the alpha adrenergic autonomic system which gives the smooth muscular tonus of the prostatic adenoma. The alpha adrenergic receptor block reduces the dynamic component, improves the clinical and urodynamic parameters determined by the infra-bladder obstruction in patients with BPH. The selective alpha 1, long acting antagonists especially, such as terazosin, offer a safe and efficient therapy for selected patients suffering from BPH. They also have the indisputable benefit of mono-administration. In this study the basic concepts of BPH treatment with terazosin are discussed.
良性前列腺增生一方面会引发与静态梗阻成分相关的临床表现，这是由于腺体大小增加所致；另一方面会引发与动态成分相关的临床表现，该动态成分由α肾上腺素能自主神经系统控制，它赋予前列腺腺瘤平滑肌张力。α肾上腺素能受体阻滞剂可减少动态成分，改善良性前列腺增生患者膀胱下梗阻所决定的临床和尿动力学参数。尤其是选择性α1长效拮抗剂，如特拉唑嗪，为患有良性前列腺增生的特定患者提供了一种安全有效的治疗方法。它们还具有单药治疗这一无可争议的优势。在本研究中，将讨论用特拉唑嗪治疗良性前列腺增生的基本概念。
